CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis

BACKGROUND: Treatment with fingolimod for multiple sclerosis (MS) reduces the efficacy of COVID-19 vaccination. The aim of this exploratory study was to evaluate whether main lymphocyte subsets and demographic features correlated to the subsequent increase in anti-SARS-CoV2 antibodies following the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiavetti, Irene, Barcellini, Lucrezia, Lapucci, Caterina, Tazza, Francesco, Cellerino, Maria, Capello, Elisabetta, Franciotta, Diego, Inglese, Matilde, Sormani, Maria Pia, Uccelli, Antonio, Laroni, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800324/
https://www.ncbi.nlm.nih.gov/pubmed/36603292
http://dx.doi.org/10.1016/j.msard.2022.104494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800324/
https://www.ncbi.nlm.nih.gov/pubmed/36603292
http://dx.doi.org/10.1016/j.msard.2022.104494

Ejemplares similares